Biogen, Inc. (BIIB)
$238.79 3.17 (1.35%)
18:21 EDT BIIB Stock Quote Delayed 15 Minutes
Previous Close $238.79
Market Cap 50.39B
PE Ratio 17.06
Volume (Avg. Vol.) 3.81M
Day's Range 234.30 - 242.21
52-Week Range 215.77 - 358.41
Dividend & Yield N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
- From InvestorPlace
- From the Web
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Biogen earnings for the second quarter of the year have BIIB stock heading higher on Tuesday thanks to a strong EPS and revenue beat.
The owners of Biogen stock will examine Biogen earnings to asss the progress that BIIB is making in key areas, including Ms and Spinraza.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
Smaller-capitalization biotechs can be riskier investments, but EXEL stock has more than just promise off and on the price chart and is readying to be purchased.
Biogen stock is under big-time pressure, with BIIB falling more than 30% over the past two trading sessions. Is the coast clear yet?
The stock charts of T, LOW and MS merit some close technical scrutiny before the trading week comes to a close. Here's what you need to know.
Biogen news about the company's decision to discontinue two Phase 3 Alzheimer’s drug studies is hitting BIIB stock hard on Thursday.
Nightstar Therapeutics stock was soaring on Monday following news that Biogen (BIIB) is acquiring the company for $877 million.
Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean for business?
These pharma stocks offer low multiples and growth catalysts that could offer relief to investors in the coming year.
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!